Good summary, but i don't agree with your analysis. The end-game will be early diagnosis of abeta over-production, IMO. You will then treat that and you won't g

Good summary, but i don't agree with your analysis. The end-game will be early diagnosis of abeta over-production, IMO. You will then treat that and you won't get alzheimers. Few will transition to Tau degeneration, and it's so much harder to fix. I don't think pharma will go big on Tau like they have with abeta. The blood tests for over-production of abeta are almost here - I expect them to be routine every few years for people over 50.